Structure Search
AG0039KT
231277-92-2 | N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine
AG0039KT
SDS
COATIP
This product is typically in stock.Please contact us for
quotation.
Request For Quotation
- mg
- g
- kg
- ml
- L
无数据
- mg
- g
- kg
- ml
- L
无数据
无数据
| CAS Number | 231277-92-2 |
| Catalog Number | AG0039KT(AGN-PC-0QZJMQ) |
| Chemical Name | N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine |
| IUPAC Name | N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine |
| InChI | InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35) |
| InChI Key | BCFGMOOMADDAQU-UHFFFAOYSA-N |
| MDL Number | MFCD09264194 |
| Molecular Formula | C29H26ClFN4O4S |
| Molecular Weight | 581.0575 |
| NSC Number | 745750 |
| SMILES | ClC=1C=C(C=CC1OCC1=CC(=CC=C1)F)NC1=NC=NC2=CC=C(C=C12)C=1OC(=CC1)CNCCS(=O)(=O)C |
| UNII | 0VUA21238F |
| Synonyms | GW 282974X,
GW 572016,
GW-282974X,
GW-572016,
GW282974X,
GW572016,
lapatinib,
lapatinib ditosylate,
N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine,
Tykerb,
Lapatinib,
231277-92-2,
Tykerb,
GW572016,
GW 572016,
Lapatinib base,
Lapatinib tosilate hydrate,
Lapatinib [INN],
Tyverb,
388082-78-8,
Lapatinib (INN),
Lapatinib free base,
GSK 572016,
UNII-0VUA21238F,
GSK572016,
MFCD09264194,
FMM,
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE,
CHEMBL554,
CHEBI:49603,
0VUA21238F,
NSC745750,
GW-572016,
NCGC00167507-01,
C29H26ClFN4O4S,
DSSTox_CID_26675,
DSSTox_RID_81812,
DSSTox_GSID_46675,
N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine,
N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine,
Q-101353,
Tycerb,
4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-,
4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-,
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine,
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine,
N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine,
CAS-231277-92-2,
GW-2016,
Lapatinib [INN:BAN],
GW 282974X,
HSDB 8209,
1xkk,
Lapatinib, Tykerb, GW572016,
N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine,
N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine,
n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine,
N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine,
Lapatinib Ditosylate/,
PubChem7650,
nchembio866-comp20,
Kinome_3684,
Kinome_3685,
AC1L4LL4,
SCHEMBL8100,
BDBM5445,
cid_208908,
GTPL5692,
QCR-63,
DTXSID7046675,
AOB5254,
EX-A402,
SYN1052,
BCFGMOOMADDAQU-UHFFFAOYSA-N,
BCPP000188,
BCPP000189,
HMS2089H10,
HMS3244N06,
HMS3244N10,
HMS3244N14,
Tykerb (TN) (Glaxo Smith Kline),
AMX10154,
BCP01874,
KS-00000GH2,
ZINC1550477,
Tox21_112505,
ABP000866,
ABP000872,
AKOS005145766,
Tox21_112505_1,
AC-1314,
AN-5195,
AN-5300,
API0003126,
BCP9000837,
BCP9000838,
CM14421,
DB01259,
NSC-745750,
RL02729,
SB16918,
NCGC00167507-02,
NCGC00167507-03,
NCGC00167507-04,
NCGC00167507-09,
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline,
913989-15-8,
AK-46487,
AS-14065,
BC677691,
EN002712,
HY-50898,
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine,
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine,
Q570,
SC-02676,
AB0005824,
AB1004631,
AX8135884,
LS-187029,
LS-187771,
ST2407069,
A3967,
AM20090641,
FT-0659650,
SW199101-5,
TL80090051,
A25184,
D08108,
J90020,
W-3749,
49311-EP2298768A1,
49311-EP2298778A1,
49311-EP2311840A1,
AB01273965-01,
AB01273965-02,
AB01273965-03,
AB01273965_04,
AB01273965_05,
277L922,
I01-1247,
SR-05000001472-1,
BRD-K19687926-001-01-7,
BRD-K19687926-379-02-5,
GW572016;GW-572016;GW 572016,
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; GSK572016; GW 572016; GW 572016X; Lapatinib; N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methanesulfonyl)ethyl]amino]methyl]-2-f,
N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine,
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine,
N-{3-chloro-4-[(3-fluoro-benzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine,
N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine,
N-{3-Chloro-4[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine,
N3-Chloro-4-(3-fluorophenyl)methoxyphenyl-6-5-(2-methylsulfonylethylamino)methyl-2-furylquinazolin-4-amine,
Lapatinib Ditosylate,
lapatinib tosilate,
Lapatinib Ditosilate,
Tykerb (TN),
Lapatinib intermediate F,
D08CDI,
lapatinib ditosilate hydrate,
Lapatinib ditosylate hydrate,
Lapatinib Ditosylate [USAN],
Lapatinib (ERBB2 inhibitor),
UNII-G873GX646R,
CHEMBL1076241,
GW572016F,
GW 572016X,
231277-92-2 (free base),
CID208908,
GW282974X,
s2111,
C29-H26-Cl-F-N4-O4-S,
LAPATINIB DITOSYLATE MONOHYDRATE,
ACN-031541,
CS-0036,
CS-O-01724,
GW-282974X,
2034B,
A8218,
A11752,
C490728,
SR-05000001472,
C29-H26-Cl-F-N4-O4-S.2C7-H8-O3-S.H2-O,
D000077341,
N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine,
|
| Complexity | 898 |
| Compound Is Canonicalized | Yes |
| Covalently-Bonded Unit Count | 1 |
| Defined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Exact Mass | 580.135g/mol |
| Formal Charge | 0 |
| Heavy Atom Count | 40 |
| Hydrogen Bond Acceptor Count | 9 |
| Hydrogen Bond Donor Count | 2 |
| Isotope Atom Count | 0 |
| Molecular Weight | 581.059g/mol |
| Monoisotopic Mass | 580.135g/mol |
| Rotatable Bond Count | 11 |
| Topological Polar Surface Area | 115A^2 |
| Undefined Atom Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| XLogP3 | 5.1 |
GHS Hazard and Precautionary Statements
| Symbol: |  |
| Hazard statements | H302 |
| Precuationary statements | P280-P305+P351+P338 |
| Siginal words | |
Certificate of Analysis
Lot Number
Product Recommendations
CERTIFICATE OF ANALYSIS
| Chemical Name: | Batch Number: | |
| Chemical Structure: | CAS Registry No: | |
| Product ID: | ||
| Manufacture Date: | ||
| Storage Temperature: | ||
| Formula: | ||
| Molecular Weight: | ||
| Quantity: |
Analysis Data:
| Test: | Result: |
Conclusion: The above product meets the specifications of Angene.
Analyst:Chase
Date:
Reviewed by:Jessie
Date:
Angene International Limited